8/8/2019 Ranbaxy Deal Sparks M

http://slidepdf.com/reader/full/ranbaxy-deal-sparks-m 1/2

Ranbaxy Deal Sparks M&A Talk for

Indian Pharma

The sale of the Indian drugmaker to Japan's Daiichicould dampen the spirit of other companies with

global dreams

Related Items

• Sikha Sharma: A Hand that Rocks ICICI Group

• Satyam Freshers Union Wants Parties to Air Concerns

• Trends: The Corporate Novelists

•

Entrepreneurship & Risk Appetite Make Indians Extraordinary• Entrepreneurship & Risk Appetite Make Indians Extraordinary

Story Tools

•  post a comment

• e-mail this story

•  print this story

• order a reprint

• suggest a story

• digg this• save to del.icio.us

The historic acquisition of the country's largest pharma company, Ranbaxy Laboratories,

 by Japanese major Daiichi Sankyo may change the Indian pharmaceutical landscapeforever.

The deal will bring in new drugs from Daiichi's portfolio into the Indian market, and

tempt Indian pharma majors, particularly generic manufacturers hitting a plateau in

overseas markets, to sell out and realise attractive valuations of the kind that Ranbaxy hassecured.

If the 5% rise in Daiichi's stock price on the Tokyo exchange, following the merger 

announcement, is anything to go by, the Japanese company is likely to turn more

competitive in the global market, absorbing Ranbaxy's low-cost manufacturing expertise.

8/8/2019 Ranbaxy Deal Sparks M

http://slidepdf.com/reader/full/ranbaxy-deal-sparks-m 2/2

Post the buyout, Daiichi Sankyo will be the second largest pharma company in India with

about 5% market share in the Rs 33,000 crore domestic pharma retail market, closely

following domestic major Cipla.

The deal will also provide Daiichi Sankyo the platform to launch its innovator products in

India at competitive prices. Recently, the Japanese major had tied up with GSK India tosell its hypertension drug, Olmesartan Medoxomil at one-fifth price in India. The deal

may expedite the company's plan to bring more of its proprietary products to India andalso use the low-cost manufacturing facilities in India.

According to ChrysCapital MD Sanjiv Kaul, an ex-Ranbaxy executive and a sector 

analyst, the deal may dampen the spirit of other Indian pharma majors who have global

aspirations. "Commercially, it is an awesome deal. However, Ranbaxy was the all-conquering Indian hero and should have been the last man standing instead of being the

first to capitulate. A huge positive for Ranbaxy but a negative for Indian pharma."

He added that the acquisition may dampen the motivation of other aspirants who want toemulate Ranbaxy's success in the global pharma industry.

Sujay Shetty, head of Life Sciences, PriceWaterhouseCoopers said the deal has

discovered the valuation of Indian companies. Promoters will find it difficult to get the

same kind of valuation at all times and the sector may see more deals, though notimmediately. "Daiichi Sankyo is an interesting combination of innovator and generic

 product basket. At some point of time, the merged entity may itself become a takeover 

candidate of global pharma majors, " he added.

To some industry observers, promoters of other Indian pharma companies should take a

cue from Ranbaxy's move. Ranjit Kapadia, Head of Research (Pharma), PrabhudasLiladhar said: "The valuation is about 20 times of Ranbaxy's EBIDTA and about 4 times

its total sales. Its a great deal. Other Indian promoters should realise that at the right placeand at the right time, they should divest their stake instead of clinging on for emotional

attachment."

Even as Indian companies have been on a active acquisition mode globally, there has

 been also been off and on rumours of global companies planning to acquire Indianmajors, such as Cipla, Aurobindo and Shasun Chemicals. Recently, the Burman family

exited the pharma business by selling its entire 65% stake to German company Fesenius

Kabi.